Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH +2.20% Earnings per Share (Diluted) is $-3.95 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 632910.76% on this metric.
ProPhase Labs's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.42.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.95.
During the past 13 years, ProPhase Labs's highest 3-Year average EPS without NRI Growth Rate was 30.00% per year. The lowest was -43.90% per year. And the median was -12.60% per year.
ProPhase Labs (OTCPK:PRPH) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ProPhase Labs Earnings per Share (Diluted) Related Terms
ProPhase Labs Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, NSTM, NOTVQ: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's PE Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's PE Ratio falls into.
ProPhase Labs Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ProPhase Labs's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-3.95 mean?
ProPhase Labs (PRPH) has a Earnings per Share (Diluted) of $-3.95 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 158 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Earnings per Share (Diluted) too high?
ProPhase Labs' current Earnings per Share (Diluted) is $-3.95. Based on the distribution chart, ProPhase Labs ranks #999999 out of 158 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Earnings per Share (Diluted) compare to IDTA and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 158 companies for Earnings per Share (Diluted). This places ProPhase Labs in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Earnings per Share (Diluted) is $-3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.91, compared to a current price of $0.05 — trading 94.4% below its estimated fair value. The current Earnings per Share (Diluted) is $-3.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Earnings per Share (Diluted) is $-3.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
